-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The author learned that the enthusiasm for institutional research in the past week has not diminished.
A number of pharmaceutical companies have recently disclosed the announcements of obtaining institutional research, including Jianfan Biological, Tonghe Pharmaceutical, Jingxin Pharmaceutical, China Resources Sanjiu, etc.
, among which Jianfan Biological has achieved super 70 investors surveyed, and Jingxin Pharmaceutical received surveys from more than 20 institutions
.
Jianfan Bio: Obtained more than 70 investors to get together for research.
On September 17, Jianfan Bio disclosed the record of investor relations activities on September 15, 2021.
Participants in the survey included GF Fund, CITIC Industrial Fund, Essence Securities, and Industrial Development.
There are more than 70 investors in China Securities, China Securities, China Securities, and Huatai Securities
.
The company is a provider of blood purification products, mainly producing hemoperfusion-related products and equipment
.
In the interactive session, the organization paid close attention to issues such as the future development plan of Jianfan Biology in the international market, the future layout of the company's nephrology products in the hospital, how to deal with centralized procurement risks, and the company's future development plan in the field of liver disease and critical illness
.
Among them, on the issue of centralized procurement, the company predicts that the company’s products will not be included in the national centralized procurement scope in the short term.
In the long run, the company is also actively responding to centralized procurement risks at the strategic and tactical levels.
In the past few years, we have continued to exert efforts in the fields of severe liver disease, critical illness, and overseas markets, and continue to increase the proportion of business; at the strategic level, the company believes that the number of patients using hemoperfusion will greatly increase, and the frequency of use will also increase.
The company’s products have 3 A heavy research support
.
Jingxin Pharmaceutical: On the same day that it received investigations from 20 institutions, Jingxin Pharmaceuticals also disclosed a record of investor relations activities, and the institutions participating in the investigation had an opinion on the company’s online e-commerce layout, innovative drugs in the field of mental nerve and cardiovascular and cerebrovascular Questions were asked about the layout, the development plan for the next year and the next, and the R&D risks under a large amount of R&D investment
.
The company is mainly engaged in the research and development, production and sales of chemical preparations (cardio-cerebrovascular drugs, nervous system drugs), traditional Chinese medicines, biological preparations, chemical raw materials, and medical devices
.
Regarding the development plan for the next year, Jingxin Pharmaceutical said that the company's development momentum comes from the steady development of its main business: the risk of centralized procurement and price reduction of finished drugs and statin products has basically landed, and will become stable with the expansion of the out-of-hospital market; With the growth of self-employed teams and the growth of pharmaceutical e-commerce in the field of nerves and digestion, they continue to maintain a good growth trend
.
The certification of APIs in overseas markets is progressing steadily, and overseas high-end markets are expected to break through growth
.
The medical device board (Shenzhen Jufeng) increased its new business and expanded its domestic and overseas markets, maintaining a steady growth trend
.
Tonghe Pharmaceutical: Obtained research from two institutions.
In addition, Tonghe Pharmaceutical obtained research from China Merchants Securities, China Europe Fund and other institutions on September 16.
Investors focused on the company’s varieties and production capacity in the next few years; the company’s current and future years Customer situation; whether to consider developing new growth areas or strategies
.
According to data, Tonghe Pharmaceutical is mainly engaged in the production of specialty chemical raw materials and intermediates
.
Regarding the current and next few years of the company’s customers, the company said that the company started from the international market and is an export-oriented enterprise.
Its market sales network covers nearly 50 countries on five continents.
Certified by Japan and South Korea, the sales of products exported to the high-end market accounted for more than 60%
.
In addition, the company actively promoted the related declaration of multiple varieties and multiple domestic customers in the Chinese market, and the domestic sales growth momentum is good
.
In the next few years, the company will continue to expand the international and domestic markets and strive for more high-quality customers
.
A number of pharmaceutical companies have recently disclosed the announcements of obtaining institutional research, including Jianfan Biological, Tonghe Pharmaceutical, Jingxin Pharmaceutical, China Resources Sanjiu, etc.
, among which Jianfan Biological has achieved super 70 investors surveyed, and Jingxin Pharmaceutical received surveys from more than 20 institutions
.
Jianfan Bio: Obtained more than 70 investors to get together for research.
On September 17, Jianfan Bio disclosed the record of investor relations activities on September 15, 2021.
Participants in the survey included GF Fund, CITIC Industrial Fund, Essence Securities, and Industrial Development.
There are more than 70 investors in China Securities, China Securities, China Securities, and Huatai Securities
.
The company is a provider of blood purification products, mainly producing hemoperfusion-related products and equipment
.
In the interactive session, the organization paid close attention to issues such as the future development plan of Jianfan Biology in the international market, the future layout of the company's nephrology products in the hospital, how to deal with centralized procurement risks, and the company's future development plan in the field of liver disease and critical illness
.
Among them, on the issue of centralized procurement, the company predicts that the company’s products will not be included in the national centralized procurement scope in the short term.
In the long run, the company is also actively responding to centralized procurement risks at the strategic and tactical levels.
In the past few years, we have continued to exert efforts in the fields of severe liver disease, critical illness, and overseas markets, and continue to increase the proportion of business; at the strategic level, the company believes that the number of patients using hemoperfusion will greatly increase, and the frequency of use will also increase.
The company’s products have 3 A heavy research support
.
Jingxin Pharmaceutical: On the same day that it received investigations from 20 institutions, Jingxin Pharmaceuticals also disclosed a record of investor relations activities, and the institutions participating in the investigation had an opinion on the company’s online e-commerce layout, innovative drugs in the field of mental nerve and cardiovascular and cerebrovascular Questions were asked about the layout, the development plan for the next year and the next, and the R&D risks under a large amount of R&D investment
.
The company is mainly engaged in the research and development, production and sales of chemical preparations (cardio-cerebrovascular drugs, nervous system drugs), traditional Chinese medicines, biological preparations, chemical raw materials, and medical devices
.
Regarding the development plan for the next year, Jingxin Pharmaceutical said that the company's development momentum comes from the steady development of its main business: the risk of centralized procurement and price reduction of finished drugs and statin products has basically landed, and will become stable with the expansion of the out-of-hospital market; With the growth of self-employed teams and the growth of pharmaceutical e-commerce in the field of nerves and digestion, they continue to maintain a good growth trend
.
The certification of APIs in overseas markets is progressing steadily, and overseas high-end markets are expected to break through growth
.
The medical device board (Shenzhen Jufeng) increased its new business and expanded its domestic and overseas markets, maintaining a steady growth trend
.
Tonghe Pharmaceutical: Obtained research from two institutions.
In addition, Tonghe Pharmaceutical obtained research from China Merchants Securities, China Europe Fund and other institutions on September 16.
Investors focused on the company’s varieties and production capacity in the next few years; the company’s current and future years Customer situation; whether to consider developing new growth areas or strategies
.
According to data, Tonghe Pharmaceutical is mainly engaged in the production of specialty chemical raw materials and intermediates
.
Regarding the current and next few years of the company’s customers, the company said that the company started from the international market and is an export-oriented enterprise.
Its market sales network covers nearly 50 countries on five continents.
Certified by Japan and South Korea, the sales of products exported to the high-end market accounted for more than 60%
.
In addition, the company actively promoted the related declaration of multiple varieties and multiple domestic customers in the Chinese market, and the domestic sales growth momentum is good
.
In the next few years, the company will continue to expand the international and domestic markets and strive for more high-quality customers
.
